BridgeMD
New treatment option for Lung Nodules
Official title Pre-Emptive Parecoxib Sodium for Pain Control During CT-Guided Lung Nodule Localization
ClinicalTrials.gov ID: NCT07675473
What this study is testing
What is PARECOXIB SODIUM?
PARECOXIB SODIUM is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for lung nodules.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- Before undergoing minimally invasive lung surgery, patients with small lung nodules often need a procedure called "CT-guided hook wire localization." This involves using a CT scanner to help doctors place a tiny wire in the lung to mark the exact location of the nodule for the surgeon. While very helpful for the surgery, this wire placement can be highly painful for patients.
- Phase 4: studies an already-approved treatment
- You might receive a placebo (an inactive treatment) instead of the study drug, decided by chance. You may not know which one you got.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Voluntarily agreed to participate in the study and signed the informed consent form approved by the Ethics Committee.
- Male or female adult patients aged 18 years or older.
- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) scheduled for Video-Assisted Thoracoscopic Surgery (VATS).
- Requires preoperative CT-guided hook wire localization of lung nodules.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
You likely can't join if
- Known history of hypersensitivity to parecoxib sodium, other COX-2 inhibitors, sulfonamides, aspirin, or other non-steroidal anti-inflammatory drugs...
- History or presence of active peptic ulcer disease, gastrointestinal bleeding, or gastrointestinal perforation.
- Severe cardiovascular diseases, including but not limited to unstable angina, history of myocardial infarction within the past 6 months, severe...
- Coagulation disorders with a bleeding tendency (e.g., hemophilia) or currently receiving full-dose anticoagulation therapy, which the investigator...
- Severe, uncontrolled pulmonary diseases (e.g., severe chronic obstructive pulmonary disease [COPD], interstitial pneumonia) that the investigator...
- Currently using other analgesic medications that cannot be discontinued during the study period.
See the full eligibility criteria
- Voluntarily agreed to participate in the study and signed the informed consent form approved by the Ethics Committee.
- Male or female adult patients aged 18 years or older.
- Histologically or cytologically confirmed non-small cell lung cancer (NSCLC) scheduled for Video-Assisted Thoracoscopic Surgery (VATS).
- Requires preoperative CT-guided hook wire localization of lung nodules.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1.
- American Society of Anesthesiologists (ASA) physical status classification of I or II.
- Fully conscious with no psychiatric or neurological disorders, and capable of fully understanding and correctly using the Visual Analog Scale (VAS) for pain assessment.
- Known history of hypersensitivity to parecoxib sodium, other COX-2 inhibitors, sulfonamides, aspirin, or other non-steroidal anti-inflammatory drugs (NSAIDs).
- History or presence of active peptic ulcer disease, gastrointestinal bleeding, or gastrointestinal perforation.
- Severe cardiovascular diseases, including but not limited to unstable angina, history of myocardial infarction within the past 6 months, severe arrhythmias, or poorly controlled hypertension.
- Coagulation disorders with a bleeding tendency (e.g., hemophilia) or currently receiving full-dose anticoagulation therapy, which the investigator believes may significantly increase the bleeding risk of the hook wire...
- Severe, uncontrolled pulmonary diseases (e.g., severe chronic obstructive pulmonary disease [COPD], interstitial pneumonia) that the investigator believes pose an unacceptable risk for the procedure.
- Currently using other analgesic medications that cannot be discontinued during the study period.
- Any other conditions that, in the investigator's judgment, might interfere with the outcome assessment or increase the risk to the subject.
The study team makes the final eligibility decision.
Where it's taking place
- Shanghai, Shanghai Municipality, China
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Shanghai, Shanghai Municipality, China. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.